SuperworthIovance Biotherapeutics IOVA
- Market cap
- $6.4B
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 19.6×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $325M
- +35% on a year ago
- Net margin
- −89.1%
- Free cash flow yield
- −4.6%
Iovance Biotherapeutics trades at 19.6× sales. Revenue was $325M over the last twelve months, up 35% on a year earlier with a −89% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $469K | $482K | $715K | $31.1M+12970% | $58.6M+12385% | $73.7M+15189% | $49.3M+6799% | $60M+93% | $67.5M+15% | $86.8M+18% | $71.4M+45% | $99.3M+66% | |
| Cost of revenue | $4.3M | $4.4M | $7.3M | $31.4M+1430% | $31.5M+626% | $45.5M+943% | $42.7M+488% | $48.9M+56% | $38.5M+22% | $43.1M−5% | $42.5M−1% | $43.6M−11% |
| Gross profit | −$3.9M | −$3.9M | −$6.5M | −$262K−86% | $27M | $28.2M | $6.6M | $11.1M | $29M+7% | $43.7M+55% | $28.9M+338% | $55.7M+403% |
| R&D | $87.5M+21% | $87.5M+9% | $79.8M−4% | $62.1M−28% | $67M−23% | $72.2M−17% | $76M−5% | $77.9M+26% | $75.2M+12% | $71.2M−1% | $62.5M−18% | $58.9M−25% |
| SG&A | $27M−3% | $29.9M+13% | $31.4M+12% | $39.6M+81% | $39.3M+46% | $42.3M+42% | $43.8M+40% | $37.6M−5% | $34.6M−12% | $36.4M−14% | $38.9M−11% | $39.3M+5% |
| −$118.4M+18% | −$121.3M+13% | −$117.7M+6% | −$101.9M−7% | −$89.1M−25% | −$86.6M−29% | −$121.2M+3% | −$113.8M+12% | −$94.9M+7% | −$73.5M−15% | −$81M−33% | −$51.9M−54% | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pre-tax income | −$115M+15% | −$118.1M+12% | −$114.4M+7% | −$98.6M−8% | −$85.1M−26% | −$77M−35% | −$118M+3% | −$109.7M+11% | −$93.7M+10% | −$71.7M−7% | −$79.7M−32% | −$48.7M−56% |
| −$1.2M | −$1.8M | −$1.4M | −$1.5M+206% | −$1.5M+22% | $1.6M | −$1.8M+31% | $2M | −$2.4M+58% | $184K−88% | −$665K−64% | −$1.4M | |
| Net income | −$113.8M+14% | −$116.4M+11% | −$113M+5% | −$97.1M−9% | −$83.5M−27% | −$78.6M−33% | −$116.2M+3% | −$111.7M+15% | −$91.3M+9% | −$71.9M−9% | −$79M−32% | −$47.3M−58% |
| −$0.46−27% | −$0.45−30% | −$0.42−16% | −$0.34−28% | −$0.28−39% | −$0.26−42% | −$0.36−14% | −$0.33−3% | n/a | n/a | −$0.19−47% | −$0.11−67% | |
| 245.8M+56% | 255.9M+55% | 266.2M+25% | 284.8M+27% | 303.3M+23% | 304.9M+19% | 322.9M+21% | 334.5M+17% | n/a | n/a | 418.5M+30% | 450.2M+35% |
Gross profit: 13 periods, Q2 FY23 to Q2 FY26: not printed by the filing, worked out from its own lines.
EPS, diluted: 9 periods, Q4 FY11 to Q4 FY24: quarter's net income to common over its shares, to the cent.
Diluted shares: 8 periods, Q4 FY11 to Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY12: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Biotechnology nearest Iovance Biotherapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| IOVAIovance Biotherapeutics | $6.4B | n/m | n/a | n/m | 19.6× | +35% | −89.1% |
| KRYSKrystal Biotech | $9.2B | 39.0× | 42.7× | n/m | 20.9× | +23% | 54.8% |
| RGENRepligen | $10B | 242× | 120× | n/m | 12.7× | +16% | 5.3% |
| TECHBIO-TECHNE | $11.4B | 63.1× | 61.6× | n/m | 9.4× | −0% | 15.0% |
| HALOHalozyme Therapeutics | $14.3B | 37.5× | 21.3× | n/m | 8.6× | +41% | 24.9% |
| NBIXNeurocrine Biosciences | $14.5B | 20.9× | 42.8× | n/m | 4.3× | +34% | 20.9% |
| EXELExelixis | $16B | 20.3× | 22.8× | n/m | 6.6× | +9% | 35.3% |
| ADMAAdma Biologics | $2.4B | 15.3× | 21.5× | n/m | 4.7× | +8% | 33.0% |
| VCELVericel | $2.2B | 92.5× | 158× | n/m | 7.1× | +23% | 7.9% |
| INCYIncyte | $23.5B | 14.7× | 36.9× | 49.5× | 4.0× | +27% | 27.7% |
| UTHRUnited Therapeutics | $25.2B | 21.0× | 14.1× | 22.0× | 8.0× | +2% | 41.6% |
| Peer median | $12.8B | 29.3× | 39.8× | 35.7× | 7.5× | +20% | 26.3% |
More on Iovance Biotherapeutics
Each number over time
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .